+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Heavy Menstrual Bleeding (HMB) - Market Insights, Epidemiology and Market Forecast - 2028

  • ID: 4911967
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 190 Pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Enteris BioPharma
  • Ferring Pharmaceuticals
  • Myovant Sciences
  • ObsEva
  • MORE
The ‘Heavy Menstrual Bleeding (HMB)- Market Insights, Epidemiology and Market Forecast - 2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Heavy Menstrual Bleeding (HMB) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Heavy Menstrual Bleeding (HMB) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2017–2028.

Heavy Menstrual Bleeding (HMB) - Disease Understanding and Treatment Algorithm

Traditionally Heavy Menstrual Bleeding (HMB) is defined as bleeding in excess of 80 mL per menstrual cycle when measured objectively, although, among women who present with the complaint of significant HMB, fewer than 50% have been objectively shown to have >80 mL of menstrual loss. HMB is a relatively uncommon complaint in younger women, yet has a prevalence of one in three women in the perimenopausal period. The gold standard for the measurement of blood in sanitary products is the extraction of hematin using a 5% sodium hydroxide solution and the estimation of the alkaline hematin content by spectrophotometry. This method is not feasible in clinical practice and has only been used in research studies. In a rigorous study in which the alkaline hematin method was used to measure menstrual blood loss, HMB was predicted on the basis of clots ≥1 inch in diameter, low ferritin, and “flooding,” defined as a change of pad or tampon more frequently than hourly.

The Heavy Menstrual Bleeding market report gives the thorough understanding of the Heavy Menstrual Bleeding by including details such as disease introduction, signs and symptoms, causes, pathophysiology, diagnosis and differential diagnosis. It also provides treatment algorithms and treatment guidelines for Heavy Menstrual Bleeding in the US and Europe.

Heavy Menstrual Bleeding (HMB) Epidemiology

Heavy menstrual bleeding (HMB) is one of the most common debilitating gynecologic disorders affecting women of reproductive age. It is subjectively defined as heavy cyclical menstrual bleeding occurring over several consecutive cycles. Empirically, it is a total blood loss of at least 80 mL per menstrual cycle or a menstrual cycle lasting longer than 7 days. The black race proves to be recurrently reported to increase uterine fibroids associated with HMB risk, by two- to threefold compare with the white race.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Heavy Menstrual Bleeding in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028 for the following aspects:
  • Prevalent Population of Heavy Menstrual Bleeding in the United States
  • Prevalent Population of Uterine Fibroids in the United States
  • Prevalent Population of Heavy Menstrual Bleeding due to Uterine Fibroids in the United States
  • Diagnosed Prevalent Population of Heavy Menstrual Bleeding in the United States
  • Diagnosed Prevalent Population of Heavy Menstrual Bleeding due to Uterine Fibroids in the United States
A retrospective population-based cohort study of women, aged 18–65 years, enrolled 2005 through 2014 in Kaiser Permanente Washington found that overall prevalence of uterine fibroids in 2014 was 9.6%, and was the highest among women aged 50–54 years, i.e., 15.9%. Black women had a higher prevalence (18.5%) than other racial/ethnic groups by Yu et al., 2018. In addition, symptomatic uterine fibroids may affect up to 25% of all women and up to 30–40% of women in the perimenopausal age range.

As per Minimally Invasive Gynecology Worldwide, (2012) by the American Association of Gynecologic Laparoscopists, Uterine leiomyomas are tumors of the myometrium that have a prevalence as high as 70–80% at age 50, but that seems to vary with a number of factors including age, race, and, possibly geographic location. Prevalence in symptom-free women has been reported to be as low as 7.8% in Scandinavian women aged 33–40, whereas in the United States, it is almost 40% in white patients and more than 60% in women of African ancestry in the same age group. Leiomyomas are listed as the diagnosis for about 39% of the approximately 600,000 hysterectomies performed each year in the United States.

Heavy Menstrual Bleeding (HMB) Drug Chapters

This segment of the Heavy Menstrual Bleeding report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment Heavy Menstrual Bleeding, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the prevalent population of Heavy Menstrual Bleeding & awareness of the disease. The overall dynamics of Heavy Menstrual Bleeding market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as ObsEva, AbbVie, Myovant Sciences and Bayer will significantly increase the market during the forecast period (2019–2028).

Heavy Menstrual Bleeding (HMB) Market Outlook

Heavy menstrual bleeding is a leading gynecologic problem, affecting more than 30% of women at some point in their life. A vigilant explanation of the cause of HMB is crucial in the management of women with HMB. There are a tremendous number of options available for the patients with HMB to reduce their blood loss and improve quality of life. The major role depends on the clinician, which is to provide proper information to facilitate women in making an appropriate choice of treatment.

The majorly employed treatment alternatives include either pharmacological interventions or surgical treatment. Pharmacological options are further bifurcated into classes such as hormonal therapies, Gonadotropin-releasing hormone (GnRH) agonists, birth control pills, Non-steroidal anti-inflammatory drugs (NSAIDs) and antifibrinolytic medicines while surgical options include endometrial ablation, uterine artery embolization (UAE), myomectomy and hysterectomy.

This segment gives a through detail of market trend of each marketed drug in late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Heavy Menstrual Bleeding in the 7MM is expected to change from 2019–2028.

Heavy Menstrual Bleeding (HMB) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Heavy Menstrual Bleeding (HMB) such as ObsEva (Linzagolix; OBE2109), AbbVie (Elagolix), Myovant Sciences (Relugolix; TAK-385), Bayer (Vilaprisan; BAY1002670) and other targeted therapies in the forecast period [2019–2028] will also create a positive impact on the Heavy Menstrual Bleeding (HMB) market.

Heavy Menstrual Bleeding (HMB) Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Heavy Menstrual Bleeding (HMB) Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Heavy Menstrual Bleeding (HMB) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Heavy Menstrual Bleeding (HMB)market
  • Organize sales and marketing efforts by identifying the best opportunities for Heavy Menstrual Bleeding (HMB)market
  • To understand the future market competition in the Heavy Menstrual Bleeding (HMB) market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Bayer
  • Enteris BioPharma
  • Ferring Pharmaceuticals
  • Myovant Sciences
  • ObsEva
  • MORE
1. Key Insights

2. Heavy Menstrual Bleeding Market Overview at a Glance
2.1. Market Share (%) Distribution of Heavy Menstrual Bleeding in 2017
2.2. Market Share (%) Distribution of Heavy Menstrual Bleeding in 2028

3. Disease Background and Overview: Heavy Menstrual Bleeding
3.1. Introduction
3.2. Causes of HMB
3.3. Polyps
3.4. Myometrial dysfunctions (adenomyosis & leiomyoma)
3.5. Malignancy and hyperplasia
3.6. Coagulopathy
3.7. Ovulatory dysfunction (hormonal causes of HMB)
3.8. Endometrial causes of HMB
3.9. Iatrogenic
3.10. Multiple common pathways that contribute to HMB
3.11. Diagnosis of Heavy menstrual Bleeding
3.12. Differential diagnosis for HMB from structural causes
3.13. Differential diagnosis with disorders of hemostasis and coagulopathy
3.14. NICE Diagnostic guidelines for HMB

4. Epidemiology and Patient Population: Key Findings
4.1. 7MM Total Patient Population of Heavy Menstrual Bleeding
4.2. 7MM Total Diagnosed Patient Population of Heavy Menstrual Bleeding

5. Country Wise-Epidemiology of Heavy Menstrual Bleeding
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Heavy Menstrual Bleeding Prevalent Population in the United States
5.1.3. Uterine Fibroids Prevalent Population in the United States
5.1.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in the United States
5.1.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in the United States
5.1.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in the United States
5.2. EU5 Countries
5.2.1. Assumptions and Rationale
5.3. Germany
5.3.1. Assumptions and Rationale
5.3.2. Heavy Menstrual Bleeding Prevalent Population in Germany
5.3.3. Uterine Fibroids Prevalent Population in Germany
5.3.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Germany
5.3.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in Germany
5.3.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Germany
5.4. France
5.4.1. Assumptions and Rationale
5.4.2. Heavy Menstrual Bleeding Prevalent Population in France
5.4.3. Uterine Fibroids Prevalent Population in France
5.4.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in France
5.4.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in France
5.4.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in France
5.5. Italy
5.5.1. Assumptions and Rationale
5.5.2. Heavy Menstrual Bleeding Prevalent Population in Italy
5.5.3. Uterine Fibroids Prevalent Population in Italy
5.5.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Italy
5.5.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in Italy
5.5.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Italy
5.6. Spain
5.6.1. Assumptions and Rationale
5.6.2. Heavy Menstrual Bleeding Prevalent Population in Spain
5.6.3. Uterine Fibroids Prevalent Population in Spain
5.6.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Spain
5.6.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in Spain
5.6.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Spain
5.7. United Kingdom
5.7.1. Assumptions and Rationale
5.7.2. Heavy Menstrual Bleeding Prevalent Population in the United Kingdom
5.7.3. Uterine Fibroids Prevalent Population in the United Kingdom
5.7.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in the United Kingdom
5.7.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in the United Kingdom
5.7.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in the United Kingdom
5.8. Japan
5.8.1. Assumptions and Rationale
5.8.2. Heavy Menstrual Bleeding Prevalent Population in Japan
5.8.3. Uterine Fibroids Prevalent Population in Japan
5.8.4. Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Japan
5.8.5. Heavy Menstrual Bleeding Diagnosed Prevalent Population in Japan
5.8.6. Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Japan

6. Treatment
6.1. Combination hormonal contraceptives
6.2. Progestins
6.2.1. In women with a history of thrombosis who are on anticoagulation
6.2.2. In women with a history of thrombosis who are not on anticoagulation
6.3. NSAID preparations
6.4. Intrauterine system releasing levonorgestrel (LNG)
6.5. Gonadotropin-releasing hormone agonists/antagonists
6.6. Tranexamic acid an anti-Fibrinolytic
6.7. Danazol
6.8. Selective progesterone receptor modulators
6.9. Combined oral contraceptive pill
6.10. Injectable progestogens
6.11. Ulipristal acetate for treatment of uterine fibroids
6.12. Surgical interventions for treatment of heavy menstrual bleeding
6.12.1. Endometrial ablation
6.12.2. Hysterectomy
6.13. Non Hormonal treatment for Anemia caused by HMB
6.14. HMB: The American College of Obstetricians and Gynecologists Recommendations for management of HMB (2019)
6.14.1. Suggestions for Hormonal Medical therapy
6.15. NICE guidelines for management of Heavy Menstrual Bleeding
6.16. Treatment Algorithm

7. Unmet Needs

8. Marketed Drugs
8.1. Lysteda (Tranexamic acid): Ferring Pharmaceuticals
8.1.1. Drug Description
8.1.2. Regulatory Milestones
8.1.3. Other Development Activities
8.1.4. Safety and Efficacy
8.1.5. Product Profile
8.2. Natazia (Estradiol valerate / Dienogest): Bayer
8.2.1. Drug Description
8.2.2. Regulatory Milestones
8.2.3. Other Development Activities
8.2.4. Safety and Efficacy
8.2.5. Product Profile
8.3. Mirena (levonorgestrel-releasing intrauterine system): Bayer
8.3.1. Drug Description
8.3.2. Regulatory Milestones
8.3.3. Other Development Activities
8.3.4. Safety and Efficacy
8.3.5. Product Profile

9. Emerging Drugs
9.1. Key Cross Competition
9.2. Linzagolix (OBE2109): ObsEva
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Product Profile
9.3. Elagolix: AbbVie
9.3.1. Product Description
9.3.2. Other Developmental Activities
9.3.3. Clinical Development
9.3.4. Product Profile
9.4. Relugolix (TAK-385): Myovant Sciences
9.4.1. Product Description
9.4.2. Other Developmental Activities
9.4.3. Clinical Development
9.4.4. Product Profile
9.5. Vilaprisan (BAY1002670): Bayer
9.5.1. Product Description
9.5.2. Clinical Development
9.5.3. Product Profile
9.6. Leuprolide: Enteris BioPharma
9.6.1. Product Description
9.6.2. Clinical Development
9.6.3. Product Profile

10. Heavy Menstrual Bleeding: 7MM Analysis
10.1. Key Findings
10.2. Market Size of Heavy Menstrual Bleeding in the 7MM
10.3. 7MM Market Outlook
10.4. United States Market Size
10.4.1. Total Market size of Heavy Menstrual Bleeding
10.4.2. Market Size by Therapies
10.5. Germany Market Size
10.5.1. Total Market size of Heavy Menstrual Bleeding in Germany
10.5.2. Market Size by Therapies
10.6. France Market Size
10.6.1. Total Market Size of Heavy Menstrual Bleeding
10.6.2. Market Size by Therapies
10.7. Italy Market Size
10.7.1. Total Market Size of Heavy Menstrual Bleeding
10.7.2. Market Size by Therapies
10.8. Spain Market Size
10.8.1. Total Market Size of Heavy Menstrual Bleeding
10.8.2. Market Size by Therapies
10.9. United Kingdom Market Size
10.9.1. Total Market Size of Heavy Menstrual Bleeding
10.9.2. Market Size by Therapies
10.10. Japan market Size
10.10.1. Total Market Size of Heavy Menstrual Bleeding
10.10.2. Market Size by Therapies

11. Case Reports
11.1. Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis
11.2. Symptoms of uterine myomas: data of an epidemiological study in Germany
11.3. Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women
11.4. Treatment patterns and health care resource utilization and costs in heavy menstrual bleeding: a Japanese claims database analysis

12. Market Drivers

13. Market Barriers

14. Appendix
14.1. Bibliography
14.2. Report Methodology

15. Researcher Capabilities

16. Disclaimer

17. About the Publisher

List of Tables
Table 1: Total Population of Heavy Menstrual Bleeding in the 7MM (2017–2028)
Table 2: Total Diagnosed Population of Heavy Menstrual Bleeding in the 7MM (2017–2028)
Table 3: Heavy Menstrual Bleeding Prevalent Population in the United States (2017–2028)
Table 4: Uterine Fibroids Prevalent Population in the United States (2017–2028)
Table 5: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in the United States (2017–2028)
Table 6: Heavy Menstrual Bleeding Diagnosed Prevalent Population in the United States (2017–2028)
Table 7: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population patients in
the United States (2017–2028)
Table 8: Heavy Menstrual Bleeding Prevalent Population in Germany (2017–2028)
Table 9: Uterine Fibroids Prevalent Population in Germany (2017–2028)
Table 10: Heavy Menstrual Bleeding Prevalent Population due to Uterine Fibroids in Germany (2017–2028)
Table 11: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Germany (2017–2028)
Table 12: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Germany (2017–2028)
Table 13: Heavy Menstrual Bleeding Prevalent Population in France (2017–2028)
Table 14: Uterine Fibroids Prevalent Population in France (2017–2028)
Table 15: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in France (2017–2028)
Table 16: Heavy Menstrual Bleeding Diagnosed Prevalent Population in France (2017–2028)
Table 17: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in France (2017–2028)
Table 18: Heavy Menstrual Bleeding Prevalent Population in Italy (2017–2028)
Table 19: Uterine Fibroids Prevalent Population in Italy (2017–2028)
Table 20: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Italy (2017–2028)
Table 21: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Italy (2017–2028)
Table 22: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Italy (2017–2028)
Table 23: Heavy Menstrual Bleeding Prevalent Population in Spain (2017–2028)
Table 24: Uterine Fibroids Prevalent Population in Spain (2017–2028)
Table 25: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Spain (2017–2028)
Table 26: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Spain (2017–2028)
Table 27: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Spain (2017–2028)
Table 28: Heavy Menstrual Bleeding Prevalent Population in the United Kingdom (2017–2028)
Table 29: Uterine Fibroids Gender-wise Prevalent Population in the United Kingdom (2017–2028)
Table 30: Heavy Menstrual Bleeding Prevalent Population due to Uterine Fibroids in the United Kingdom(2017–2028)
Table 31: Heavy Menstrual Bleeding Diagnosed Prevalent Population in the United Kingdom (2017–2028)
Table 32: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in the United Kingdom (2017–2028)
Table 33: Heavy Menstrual Bleeding Prevalent Population in Japan (2017–2028)
Table 34: Uterine Fibroids Prevalent Population in Japan (2017–2028)
Table 35: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Japan(2017–2028)
Table 36: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Japan (2017–2028)
Table 37: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Japan (2017–2028)
Table 38: Medical treatment regimens for acute Heavy Menstrual Bleeding
Table 39: Comparison of Emerging Drugs Under Development
Table 40: Linzagolix (OBE2109), Clinical Trial Description
Table 41: Elagolix, Clinical Trial Description
Table 42: Relugolix, Clinical Trial Description
Table 43: Vilaprisan, Clinical Trial Description
Table 44: Leuprolide, Clinical Trial Description
Table 45: Seven Major Market Size of Heavy Menstrual Bleeding in USD Million (2017–2028)
Table 46: United States Market Size of Heavy Menstrual Bleeding , USD Million (2017–2028)
Table 47: Market size of Heavy Menstrual Bleeding by therapies in the United States, in USD Million (2017–2028)
Table 48: Market Size of Heavy Menstrual Bleeding in Germany, in USD Million (2017–2028)
Table 49: Market size of Heavy Menstrual Bleeding by therapies in Germany, in USD Million (2017–2028)
Table 50: Market Size of Heavy Menstrual Bleeding in France, in USD Million (2017–2028)
Table 51: Market size of Heavy Menstrual Bleeding by therapies in France, in USD Million (2017–2028)
Table 52: Market Size of Heavy Menstrual Bleeding in Italy, in USD Million (2017–2028)
Table 53: Market size of Heavy Menstrual Bleeding by therapies in Italy, in USD Million (2017–2028)
Table 54: Market Size of Heavy Menstrual Bleeding in Spain, in USD Million (2017–2028)
Table 55: Market size of Heavy Menstrual Bleeding by therapies in Spain, in USD Million (2017–2028)
Table 56: Market Size of Heavy Menstrual Bleeding in the UK, in USD Million (2017–2028)
Table 57: Market size of Heavy Menstrual Bleeding by therapies in the United Kingdom, in USD Million (2017–2028)
Table 58: Market Size of Heavy Menstrual Bleeding in Japan, in USD Million (2017–2028)
Table 59: Market size of Heavy Menstrual Bleeding by therapies in Japan, in USD Million (2017–2028)

List of Figures
Figure 1: Pathways that contribute to HMB
Figure 2: Diagnosis of heavy menstrual bleeding
Figure 3: Total Patient Population of Heavy Menstrual Bleeding in the 7MM (2017–2028)
Figure 4: Total Diagnosed Patient Population of Heavy Menstrual Bleeding in the 7MM (2017–2028)
Figure 5: Heavy Menstrual Bleeding Prevalent Population in the United States (2017–2028)
Figure 6: Uterine Fibroids Prevalent Population in the United States (2017–2028)
Figure 7: Heavy Menstrual Bleeding due to Uterine Prevalent Population Fibroids in the United States (2017–2028)
Figure 8: Heavy Menstrual Bleeding Diagnosed Prevalent Population in the United States (2017–2028)
Figure 9: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in the United States (2017–2028)
Figure 10: Heavy Menstrual Bleeding Prevalent Population in Germany (2017–2028)
Figure 11: Uterine Fibroids Prevalent Population in Germany (2017–2028)
Figure 12: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Germany (2017–2028)
Figure 13: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Germany (2017–2028)
Figure 14: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Germany (2017–2028)
Figure 15: Heavy Menstrual Bleeding Prevalent Population in France (2017–2028)
Figure 16: Uterine Fibroids Prevalent Population in France (2017–2028)
Figure 17: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in France (2017–2028)
Figure 18: Heavy Menstrual Bleeding Diagnosed Prevalent Population in France (2017–2028)
Figure 19: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in France (2017–2028)
Figure 20: Heavy Menstrual Bleeding Prevalent Population in Italy (2017–2028)
Figure 21: Uterine Fibroids Prevalent Population in Italy (2017–2028)
Figure 22: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Italy (2017–2028)
Figure 23: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Italy (2017–2028)
Figure 24: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Italy (2017–2028)
Figure 25: Heavy Menstrual Bleeding Prevalent Population in Spain (2017–2028)
Figure 26: Uterine Fibroids Prevalent Population in Spain (2017–2028)
Figure 27: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Spain (2017–2028)
Figure 28: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Spain (2017–2028)
Figure 29: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Spain (2017–2028)
Figure 30: Heavy Menstrual Bleeding Prevalent Population in the United Kingdom (2017–2028)
Figure 31: Uterine Fibroids Prevalent Population in the United Kingdom (2017–2028)
Figure 32: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in the United Kingdom (2017–2028)
Figure 33: Heavy Menstrual Bleeding Diagnosed Prevalent Population in the United Kingdom (2017–2028)
Figure 34: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in the United Kingdom (2017–2028)
Figure 35: Heavy Menstrual Bleeding Prevalent Population in Japan (2017–2028)
Figure 36: Uterine Fibroids Prevalent Population in Japan (2017–2028)
Figure 37: Heavy Menstrual Bleeding due to Uterine Fibroids Prevalent Population in Japan (2017–2028)
Figure 38: Heavy Menstrual Bleeding Diagnosed Prevalent Population in Japan (2017–2028)
Figure 39: Heavy Menstrual Bleeding due to Uterine Fibroids Diagnosed Prevalent Population in Japan (2017–2028)
Figure 40: Synthesis and signalling of prostaglandins
Figure 41: The fibrinolytic pathway
Figure 42: Treatment Algorithm for HMB.
Figure 43: Unmet Needs of HMB
Figure 44: Seven Major Market Size of Heavy Menstrual Bleeding in USD Million (2017–2028)
Figure 45: Market Size of Heavy Menstrual Bleeding in the United States, USD Millions (2017–2028)
Figure 46: Market size of Heavy Menstrual Bleeding by therapies in the US, in USD Million (2017–2028)
Figure 47: Market Size of Heavy Menstrual Bleeding in Germany, USD Million (2017–2028)
Figure 48: Market Size of Heavy Menstrual Bleeding by therapies, in Germany, in USD Million (2017–2028)
Figure 49: Market Size of Heavy Menstrual Bleeding in France, USD Million (2017–2028)
Figure 50: Market Size of Heavy Menstrual Bleeding by therapies, in France, in USD Million (2017–2028)
Figure 51: Market Size of Heavy Menstrual Bleeding in Italy, USD Million (2017–2028)
Figure 52: Market Size of Heavy Menstrual Bleeding by therapies, in Italy, in USD Million (2017–2028)
Figure 53: Market Size of Heavy Menstrual Bleeding in Spain, USD Million (2017–2028)
Figure 54: Market Size of Heavy Menstrual Bleeding by therapies in Spain, in USD Million (2017–2028)
Figure 55: Market Size of Heavy Menstrual Bleeding in the UK, USD Million (2017–2028)
Figure 56: Market Size of Heavy Menstrual Bleeding by therapies in the UK, in USD Million (2017–2028)
Figure 57: Market Size of Heavy Menstrual Bleeding in Japan, USD Million (2017–2028)
Figure 58: Market Size of Heavy Menstrual Bleeding by therapies in Japan, in USD Million (2017–2028)
Figure 59: Market Drivers
Figure 60: Market Barriers

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ferring Pharmaceuticals
  • ObsEva
  • AbbVie
  • Myovant Sciences
  • Bayer
  • Enteris BioPharma
Note: Product cover images may vary from those shown
Adroll
adroll